CoChat

Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications

Open access
Gandara, David R., Li, Tianhong, Lara, Primo N., Kelly, Karen, Riess, Jonathan W., Redman, Mary W., Mack, Philip C. · 2014 · Clinical Lung Cancer
Cited by 83

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

In the emerging era of targeted therapy for advanced stage non-small cell lung cancer (NSCLC), it is becoming increasingly important to anticipate potential underlying driver oncogene alterations at the time of initial diagnosis and tumor tissue acquisition, so that patients can be selected in a timely fashion for first line tyrosine kinase inhibitor (TKI) therapy if their cancers are found to harbor activating mutations in the epidermal growth factor receptor (EGFR) gene or gain-of-function rearrangements of anaplastic lymphoma kinase (ALK). However, despite clear benefits for TKI therapy over chemotherapy in these settings, eventual emergence of acquired resistance and progressive disease (PD) is universal. How to best approach oncogene-driven NSCLC at the time of acquired resistance to initial TKI therapy is an increasingly complex question, due to variability in mechanisms of resistance, extent of PD and inter- and intra-patient tumor heterogeneity. Here we propose an approach to subtyping PD in the setting of acquired resistance as well as subsequent clinical implications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cllc.2013.10.001

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Gandara, D. R., Li, T., Lara, P. N., Kelly, K., Riess, J. W., Redman, M. W., & Mack, P. C.
Venue
Clinical Lung Cancer
Publisher
Elsevier BV
Published
2014-01
Volume
15
Issue
1
Pages
1-6
ISSN
1525-7304 (ISSN-L)
OpenAlex
W2005665711
Cited by
83
References
12
FWCI
5.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.